{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["86"],"submitter":["Hohberger B"],"pubmed_abstract":["<h4>Background</h4>Rovunaptabin neutralises functional autoantibodies targeting G-Protein coupled receptors (GPCR-fAAbs), observed in patients with Post-COVID syndrome. As we hypothesise an improvement of PCS by rovunaptabin, the aim of reCOVer was to investigate safety, tolerability, and clinical effects of rovunaptabin in PCS patients.<h4>Methods</h4>reCOVer is a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical investigator initiated trial with 1350 mg rovunaptabin with additional cross-over at the Universitätsklinikum Erlangen, Germany. The trial was registered in EudraCT, 2022-001781-35. Screening was done between 21·11·2023 and 25·06·2024. Eligible participants (18-80 years) showed GPCR-fAAbs, at least 3/8 defined PCS symptoms persisting ≥3 mon"],"journal":["EClinicalMedicine"],"pagination":["103358"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12304723"],"repository":["biostudies-literature"],"pubmed_title":["Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT)."],"pmcid":["PMC12304723"],"pubmed_authors":["Herrmann M","Stog A","Ruhl E","Kruse F","Skornia A","Lakatos P","Schottenhamml J","Rech J","Bartsch A","Hohberger B","Wytopil M","Ganslmayer M","Heimke-Brinck R","Hofmann S","Maas S","Merkel C","Strobel A","Schmidt KG","Knauer T","Harrer T","Zeisberg V","Borst T","Mardin C"],"additional_accession":[]},"is_claimable":false,"name":"Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT).","description":"<h4>Background</h4>Rovunaptabin neutralises functional autoantibodies targeting G-Protein coupled receptors (GPCR-fAAbs), observed in patients with Post-COVID syndrome. As we hypothesise an improvement of PCS by rovunaptabin, the aim of reCOVer was to investigate safety, tolerability, and clinical effects of rovunaptabin in PCS patients.<h4>Methods</h4>reCOVer is a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical investigator initiated trial with 1350 mg rovunaptabin with additional cross-over at the Universitätsklinikum Erlangen, Germany. The trial was registered in EudraCT, 2022-001781-35. Screening was done between 21·11·2023 and 25·06·2024. Eligible participants (18-80 years) showed GPCR-fAAbs, at least 3/8 defined PCS symptoms persisting ≥3 mon","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-03-31T11:04:56.787Z","creation":"2025-08-27T03:11:18.927Z"},"accession":"S-EPMC12304723","cross_references":{"pubmed":["40735347"],"doi":["10.1016/j.eclinm.2025.103358"]}}